

WALDER WYSS ADVISED VERSANT VENTURES IN MATTERHORN BIOSCIENCES LAUNCHING

Posted on 12 August 2020





Category: Deal & transactions

Tags: <u>Alexander Gutmans</u>, <u>Ex-Featured</u>, <u>Jessica Aeschbach Flórez</u>, <u>Karina Tschon</u>, <u>Markus R. Frick</u>, <u>Robert von Rosen</u>, <u>Walder Wyss</u>



Matterhorn Biosciences, a Swiss biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue origins, has received a financing of USD 30 million from **Versant Ventures**. It is the most recent company to be launched out of Versant's Ridgeline Discovery Engine based in Basel, Switzerland.

The advisor

Walder Wyss advised Versant Ventures in connection with this transaction. The team was led by partner Alexander Gutmans (Transaction/M&A & Venture Capital - pictured) and partner Robert von Rosen (Transaction/M&A & Venture Capital) and included partner Markus R. Frick (IP/IT), senior associate Jessica Aeschbach Flórez (Transaction/M&A) and associate Karina Tschon (Transaction/M&A).